[1]
Jfri, A., Meltzer, R. and Guggina, L. 2022. Runner Up: Incidence of Cutaneous Adverse Events with PI3K-Akt-mTOR Pathway Inhibitors: A Systematic Review and Network Meta-Analysis. SKIN The Journal of Cutaneous Medicine. 6, 3 (May 2022), s39. DOI:https://doi.org/10.25251/skin.6.supp.39.